News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A shameful Post on NWBO MB by the So-Called Charity Investor?? Don't Trust this thing & If there is a POS. that is NVCR imo.. SMH
"In other words, thermo NEEDS you to flip back around to help pump this POS. He and the other "friendly" investors continue to dump warrants/preferred conversions, common and cover shorts! IMHO
You want to know why. Here is the reason. Each member of C-suite has been dumping their position like crazy. Which patient in sane category would wear this armor thingy for minimum 18 hours a day if there is an excellent option that three shots will completely reprogram the immune system and trigger massive T-cells (CD4 & CD8) attack on tumor cells?
Post Below is By the Charity Talker, who Keeps Bashing NWBO???..
" I want the World to be a better place and want to live to see breakthroughs in the treatment of ALL cancer, we aren't there yet but I hope we are close"
SMH... You blow your Cover Charity Investor... LOL
The so-called "FOR CHARITY INVESTORS" find it necessary to go & BASH NWBO.. A Cancer Cure Company
Humm.. What a hypocrite!!
https://www.tipranks.com/news/the-fly/novocure-management-to-meet-with-piper-sandler …Plotting to get this share price higher. Pressure needs to be put to oust the CEO. That would send it flying! Tutes can’t be to happy about how the share price has been dismantled. Stay tuned!
Piper Sandler analyst Jason Bednar upgraded Novocure to Overweight from Neutral with an unchanged price target of $45. The "overwhelming pressure" on the shares has pushed the stock to levels where the risk/reward is "simply too attractive to remain on the sidelines" ahead of the soon-to-be-released Phase 3 data in recurrent ovarian cancer, the analyst tells investors in a research note. The firm sees "reasons to be upbeat" on INNOVATE-3 data and likes the potential for shares to move higher from current levels.
Is It WAY Oversold - OR - Was It WAY Overvalued??
Sad to see you giving thumbs up to EXW on NWBO MB... LOL
This was a great pump, making many, mostly insiders/funders/backers a fortune, while failing to deliver on the hope they promised IMO.
The cat is out of the hat....
Lower lows & then some... is in books IMO
I don’t get mad as hell. I’m a Christian and the joy of the Lord is my strength. If all I own goes belly up I still have joy. Hope you can say the same. God bless.
dstock - that Legend poster you responding to is a disgruntled NVCR investor.. mad as hell for losing..
This Therapeutic Pretender Going Way Lower IMO
Appreciate it! God bless and take care!
Consensus average price target is $101.23, but have fun while you can. https://www.benzinga.com/quote/NVCR/analyst-ratings
lol. Learningcure2020, a LIFTIME, paid NWBO Basher Does Not Realized that their Constant Years of Attempt to Diminish NWBO Technology has massively Backfired....
Yes, Many NWBO Investors Got Tired, are here & Everywhere giving shameless BS posters like you, a test of your own Dumb Trashy Approach against NWBO...
You all, Particularly you, don't need anyone to try to embarrass you, you have done and doing a great job showing who you are = a waist of a being!!
Yes it was! I own it! But I will hold for better days! God bless and take care!
Wow you are an idiot.
The selling records of the NVCR managment. Pay special attention to the amount of money they made after May 28, 2018 on which the first results from p3 trial of DCVax-L were published. It seems to me every management crew of NVCR is ready to abandon the ship.
Michael J. Ambrogi has been appointed as Vice President - Senior Technology Fellow of the Company effective 9/1/2020. He has been our Chief Operating Officer since 2010 and previously served as our U.S. General Manager from 2006 to 2010. Mr. Ambrogi has overall responsibility for our ongoing operations, engineering, manufacturing, service and human resources activities worldwide.
Asaf Danziger has served as Chief Executive Officer of Novocure since 2002 and has been a director of Novocure since 2012. Mr. Danziger has led the company and the development of TTFields therapy from preclinical testing through regulatory approvals to commercial sales in Europe and the United States.
Charles G. Phillips III has been a director of Novocure since 2012 and has served on our audit committee and as the chairperson of our compensation committee since 2012.
Mr. Doyle has served as our Executive Chairman since 2016, as Chairman of the Board since 2009 and as a member of our Board of Directors since 2004.
Dr. Eilon Kirson joined Novocure in 2002 and served as Chief Medical Officer until 2012 when he was promoted to Chief Science Officer and Head of Research and Development.
Dr. Ely Benaim joined Novocure in April 2019 and serves as Chief Medical Officer.
Frank Leonard has served as Novocure’s Chief Development Officer since September 2020. This newly created executive role has responsibility for engineering, product development, business development, and the overall strategic and operational leadership of Novocure’s innovation platforms.
Gabriel Leung has been Vice Chairman and a director of Novocure since 2011.
Todd Longsworth joined Novocure in 2012 and serves as General Counsel.
Wilco Groenhuysen has served as Novocure’s Chief Operating Officer since September 2020. He is responsible for the general and administrative management of the company, the strategic and operational leadership of Novocure’s supply chain, warehousing and distribution, quality assurance and information technology operations. Mr. Groenhuysen is tasked to ensure organizational readiness in anticipation of the completion of four phase 3 clinical trials over the next few years.
https://investorshub.advfn.com/uimage/uploads/2023/7/30/iqylhAsaf_Danziger_NVCR.png
NVCR Out of the Gate on Massive HYPE, Heading to Pennyland on trial findings that the tech is Not Good Enough to waste time on IMO
Here is the dissertation by Joseph Anotnios who was the only Ph.D. student under the direct guidance of Dr. Linda Liau.
https://escholarship.org/content/qt0t37x26s/qt0t37x26s.pdf
Take a look at the results from mouse model. The green line corresponds to the currently undergoing combo trial at UCLA.
https://classic.clinicaltrials.gov/ct2/show/NCT04201873?cond=atl-dc&draw=2&rank=1
People always say that medicine success on animal models would not translate to the one on humans. Here is the amazing part. In the case of DCVax-L, the success on animal models translates.
DCVax-L alone was successful on animal models. Then success was achieved in p1 and p3 trial.
DCVax-L + Poly-ICLC was successful on mouse models. in the human trial, five out of nine patients live over 10 years after three doses of the vaccine within 28 days. No SOC was involved.
https://classic.clinicaltrials.gov/ct2/show/NCT01204684?cond=glioblastoma&spons=Jonsson&draw=2&rank=15
DCVax-L + Poly-ICLC + Keytruda was successful on mouse models too. Likewise we see the incredible data on rGBM patients.
https://classic.clinicaltrials.gov/ct2/show/NCT04201873?cond=atl-dc&draw=2&rank=1
This trial needs elaboration. As a matter of fact, the preliminary results from this trial were so successful that after March 2021 which was the last time the PI, Timothy Cloughesy reported to Merck, all the puzzles started moving. Kevin Duffy joined Regeneron. Oncovir who owns the patent of poly-iclc hired several high-caliber professionals. It should be noted that National Cancer Institute is also the sponsor of the trial. No doubt Timothy would report to NCI too. People who really have interest may check who was later promoted to be the director of NCI and later the director of NIH.
|
Followers
|
28
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
559
|
|
Created
|
10/07/15
|
Type
|
Free
|
| Moderators | |||
AI
